

### **Pediatric Collaborative Call**

January 30, 2025



#### Agenda

- Updates from TIDX-QI Coordinating Center, Osagie Ebekozien, MD, MPH and Nicole Rioles, MA
- Center Presentations
  - SUNY, David Hansen, MD
  - Nemours Delaware, Patrick Hanley, MD
  - Texas Children's Hospital, Daniel DeSalvo, MD, Sarah Lyons, MD, and Selorm Dei-Tutu, MD



#### **Pediatric Qualitative Opportunity**

- The University of Pittsburgh is conducting a qualitative study with a national sample of pediatric diabetes centers/practices about their current processes for working with schools. This study is intended to complement the survey data that your center may have shared through the TIDX annual survey. The information learned through this research will be used to help develop strategies to implement interventions for diabetes in the school setting.
- Interval interviews are anticipated to last between 30-60 minutes
- This study is being conducted by Dr. Christine March (PI), who can be reached at 412-692-9156 or <u>Christine.eklund@chp.edu</u>, if you have any questions.





#### 2024 Invoicing

For your Statements of Work with T1D Exchange, all invoices for deliverables completed on or before December 31, 2024, must be invoiced on or before 5pm EST March 1, 2025. Please work with your finance teams to ensure that we receive your invoices as we will be unable to process past due invoices for Calendar year 2024 after 3/1/2025.

Invoice for payment following the deliverables schedule in 1.C and/or 1.D and include deliverable number and date. All payments will be made through electronic funds transfer (EFT). Please include your banking information on invoice.

- 1.Bank account name & address
- 2.Bank account number
- 3.Bank account routing number

Invoices should be sent via email attachment.

- To: <u>t1dxap@t1dexchange.org</u> CC: <u>nrioles@t1dexchange.org</u>
- linda.crasco@t1dexchange.org
- rweathers@t1dexchange.org

Kindly forward this reminder to your finance contacts so that they are aware of the deadline.



#### Thank you!

Thank you for a wonderful journey together over the past 7 years. I truly appreciate each and everyone of you who have made my time at TID Exchange so memorable!

Please stay connected via LinkedIn <u>(1) Osagie</u> <u>Ebekozien MD, MPH |</u> <u>LinkedIn</u> or email <u>Osagie.ebeks@gmail.com</u>































FITNESS







# **Center Presentation**





# **Diabetes Resources Education** and Management Support (DREAMS): Program for Adolescents at **High Risk of Diabetic Ketoacidosis**





## **Program Staff**

- Pls: Dr. David Hansen, Dr. Roberto Izquierdo
- Diabetes Care and Education Specialists: Ann-Marie Hudy, Janine Robbins, Eden Dodd, Cortney Parry
- Psychologist: Dr. Ashely McDuffee
- Social Worker: Beth Evans
- Child Life Specialist: Margaret Nellis
- Registered Dietician: Kathryn Lewis
- QI Team: Jerusha Owusu-Barnie, Joe Erardi
- Management: Beth Wells, Jess Reis, Melissa Stacy



## Joslin Diabetes Center at SUNY Upstate Medical University

- In 2024
  - 3571 individuals with at least 1 visit (Type 1, Type 2, and all other endocrine)
  - 844 individuals with Type 1 had at least 1 visit
  - 84 individuals with Type 1 newly diagnosed
  - 47.4 % are on public insurance
  - 76.8% NH White
  - 9.4% NH Black
  - 7.0% Hispanic





#### Purpose

- The program is intended to give additional support to individuals with diabetes who have been admitted to the hospital with diabetic ketoacidosis (DKA) or who have an HbA1c that is above 9.0% and at risk for DKA.
- AIM: Decrease DKA admissions and improve HbA1c of program participants and increase quality of life for high-risk patients over 8 months of program enrollment.





Patients with high risk of DKA and high HbA1c

### Program Timeline/ PDSA Cycles

June/July 2019: Develop Initial Enrollment Criteria, Education Curriculum, and return to usual care protocol.	Aug 2020 Second C of 16 begi	N A P Cohort P ins. D	lov 2022: Rolling dmissions begin. 7 articipants enrolled. rogram rebranded to REAMS.	Novemb Added pa to progra	er 2023: sychologist m
Aug 2019: Be of 16 particip Program initi Diabetes We Program.	egan cohort bants. ally called Illness	Fall 2022: Lessons Learned & changes to curriculum and rolling admission	Fall 2023 Learned changes and eligi added	3: Lessons #2 and to curriculum bility criteria.	November 2023: Began Cohort #4 (DREAMS #2): Rolling admission of 13 participants



### Enrollment Process for Cohorts 1 & 2





### Education Curriculum for Cohorts 1 & 2





#### **DWP Return to Usual Care Criteria for Cohort 1 & 2**



#### Cohort 1: DKA Data prior to DWP and post DWP





#### Pre and Post Cohort 2: HbA1C





### Lessons Learned from Cohorts 1 & 2

- Change in scheduling process to decrease no shows and rescheduling
- The program was effective for those who attended and completed the program
- We need to make our program more accessible for patients who are already facing many barriers
- Don't need all 6 visits, decreasing the number of visits may help participation



### DREAMS

- To increase participation and reduce those returning to usual care:
  - Reduced the number of visits from  $6 \rightarrow 4$ .
  - Changed scheduling process to have some visits follow a visit with a clinician.



## New Curriculum for Rolling Admissions





	Completed DREAMS	Returned to Usual Care (Did not complete program)	Total Enrollment
n	4	3	7
Age, mean <u>+</u> SD (years)	15.3 <u>+</u> 1.30	19.3 <u>+</u> 0.47	17 <u>+</u> 2.27
Female % (n)	50.0 (2)	66.7 (2)	57.1 (4)
Race			
White % (n)	25 (1)	33.3 (1)	28.6 (2)
Black/African American % (n)	75 (3)	66.7 (2)	71.4 (5)
Insurance			
Public % (n)	75.0 (3)	100.0 (3)	85.7 (6)
Private % (n)	25.0 (1)	0 (0)	14.3 (1)
HbA1c (%) [mean] at start of program <u>+</u> SD	14.7 <u>+</u> 2.4	12.1 <u>+</u> 2.6	13.5 <u>+</u> 2.8
HbA1c (%) [mean] ~6-12 months after completion or return to usual care	14.4 <u>+</u> 2.6	14.5 <u>+</u> 0.7	14.4 <u>+</u> 2.0

#### HbA1c (%) Completed Program and Returned to Usual Care



Golisano Children



20.0

#### **DKA Admissions**





#### Lessons Learned DREAMS Cohort 1

- Barriers to self-management and attending appointments are multifaceted. Changes to curriculum and reduction of visits appears to not mitigate barriers.
- No reduction in HbA1c among those who completed (n=4) program but those that returned to usual care (n=3) saw an increase 6-12 months later.
- Reduction in enrollment in part because of reduction in DKA admissions in total clinic population.
- Some participants may have benefited from extra two visits that were discontinued.



## DREAMS Cohort # 2 (11/2023 to Current)

- Added two visits back to curriculum as optional; determined by education staff if they deemed extra visits needed.
- Added psychologist to program.
- Involved social worker with parents/guardians of those in program. (Parental Goals)
- Changed eligibility criteria. Allow those with HbA1c of > 9.0% to enroll or by referral from clinician.
- Eliminated return to usual care protocol. Return to usual care will be discussed with group on case-by-case basis.
- New intervention chart created in Epic to keep track of topics covered in each DREAMS visit



#### Problem List

#### Care Coordination Note

Search for new problem

122 E

#### Joslin Dreams Intervention Chart

DREAMS Interventions	Visit #1	Visit #2	Visit #3	Visit #4	Visit #5	Visit #6
DME Handouts - Contact info	ä	<b></b>	ä	Ċ.	Ċ.	Ċ.
Program Details Handout	Ö	i i i	Ċ.	Ċ.	i i i	i i i
Transportation	Ö	i i i	Ċ.	Ċ.	i i i	Ċ.
SW Referral	Ċ.	<b>⊟</b>	Ċ.	Ċ.	<b>⇔</b>	i i i i i i i i i i i i i i i i i i i
Diabetes education reviewed	Ċ.	<b>⇔</b>	Ċ.	Ċ.	<b>⇔</b>	i i i i i i i i i i i i i i i i i i i
CGM	Ċ.	<b>⇔</b>	Ċ.	Ċ.	<b>⇔</b>	i i i i i i i i i i i i i i i i i i i
Pump	Ċ.	i i i	Ċ.	Ċ.	i i i	i i i
InPen	Ċ.	i i i	Ċ.	Ċ.	i i i i i i i i i i i i i i i i i i i	i i i
Hybrid Closed Loop System	Ċ.	<b></b>	Ċ.	Ċ.	i i i i i i i i i i i i i i i i i i i	i i i i i i i i i i i i i i i i i i i
A1c and TIR Handout	Ċ.	i i i	Ċ.	Ċ.	i i i i i i i i i i i i i i i i i i i	i i i
Personalized goal setting	Ċ.	i i i	Ċ.	Ċ.	i i i	i i i
Exercise handout/plan	Ċ.	i i i	i i	i i i	i i i	i i i
RD visit	Ċ.	Ċ.	Ċ.	i i i i i i i i i i i i i i i i i i i	Ċ.	Ċ.
Child Life Interaction	Ċ.	Ċ.	Ċ.	Ċ.	Ċ.	Ċ.
Peer-to-peer support	Ċ.	Ċ.	Ċ.	Ċ.	Ê	Ċ.
Increase parental supervision	Ċ.	Ċ.	Ċ.	Ċ.	Ê	Ċ.
Training of other caregivers	Ċ.	i i	Ê	Ċ.	Ê	Ċ.
Contact information via My Chart	Ċ.	Ċ.	Ċ.	Ċ.	Ê	Ċ.
Community resources	Ċ.	Ċ.	Ê	Ċ.	Ê	Ċ.
Insulin regimen changes	Ċ.	Ċ.	Ċ.	Ċ.	Ċ.	Ċ.
Safety Quick Card	Ċ.	i i	Ê	Ċ.	Ċ.	Ċ.
Behavioral Health Interaction	ä	ä	Ċ.	Ċ.		Ċ.



	Completed Program	Returned to Usual Care (Did not complete program)	Total Enrollment
n	4	3	13
Age, mean <u>+</u> SD (years)	15.5 <u>+</u> 1.12	16 <u>+</u> 1.63	15.2 <u>+</u> 2.01
Female % (n)	75 (3)	66.7 (2)	76.9 (10)
Male % (n)	25 (1)	33.3 (1)	23.1 (3)
Race			
White % (n)	75 (3)	66.7 (2)	69.2 (9)
Black/African American % (n)	0 (0)	33.3 (1)	15.4 (2)
Other % (n)	25 (1)	0(0)	15.4 (2)
Insurance			
Public % (n)	50 (2)	66.7 (2)	76.9 (10)
Private % (n)	50 (2)	33.3 (1)	23.1 (3)
HbA1c (%) [mean] at start of program <u>+</u> SD	11.7 <u>+</u> 1.15	11.8 <u>+</u> 0.97	11.6 <u>+</u> 1.66
HbA1c (%) [mean] at last visit or when returned to usual care + SD	10.0 <u>+</u> 1.90	12.5 <u>+</u> 0.85	11.1 <u>+</u> 1.96

#### HBA1c(%) of those that completed DREAMS



Pre visit A1c Visit 6 A1c



#### CGM Metrics at Start of Program

#### CGM Metrics at Program Completion



#### **DKA Admissions**



### Next Steps/Conclusions

- Finish visits/complete program for those enrolled in recent cohort
  - Analyze outcome measures of full cohort
- Determine participant satisfaction of program and get feedback from those that completed program
- Continue to try new interventions to address barriers



# **Center Presentation**





# Nemours Children's Hospital, Delaware

Patrick Hanley, MD, MSHQS January 30<sup>th</sup>, 2025


# About Us

- Nemours joined as three different sites last year:
  - <u>Delaware</u>: Site PI Patrick Hanley
  - <u>Orlando:</u> Site PI Neha Vyas
  - Jacksonville: Site PI Monica Mortensen



# Nemours Children's Hospital, Delaware

## **Multidisciplinary Team**

- Ped Endo Physicians: 10 (6.67 cFTE)
- Nurse Practitioners: 4 (3.1 cFTE)
- Physician Assistant: 1 (0.8 cFTE)
- Social Worker: 1 (1.0 cFTE)
- Psychologist: 1 (0.2 1cFTE)
- Endo fellow: 1 (July 2025)
- CDCES (3.1 FTE total)
  - Nurses 2.1 FTE
  - Dietitians 1.0 FTE

## **Volume and Demographics**

- 1056 patients with T1D
- Average ~ 110 new onset T1D per year

Insurance: 31% Medicaid

## Race/Ethnicity (T1D & T2D)



## **Contact Names**

## Site Pl

- Patrick Hanley, MD, MSHQS
- <u>Patrick.Hanley@nemours.org</u>

## QI Site Coordinator:

- Ashley Medina, DHSc, MHA, CPHQ, CPPS, PMP
- Ashley.Medina@nemours.org

## **Other Team Members:**

- Jeffrey Myers (Bioinformatician)
- Jeffrey.Myers@nemours.org



# Diabetes SmartForm & Learning Health System (LHS)

- Review sample Diabetes SmartForm patient in Epic BLD
- Review features in Diabetes LHS
- Knowledge Base LHS



## **Process Measure: Patient Scheduling**



# of T1D patients not scheduled and not seen in 6 months



# Continuous Glucose Monitor Utilization Project AIMs

Investigate reasons for decreased CGM utilization.

Increase CGM utilization in patients with HbA1c
 >8.5% by 10% by July 2024.



# Baseline Data for CGM Utilization

CGM Prescribed	<u>A1c &gt; 8.5% (N=322)</u>	<u>Percent of</u> <u>Total</u>	<u>A1c &lt; 8.5%</u> (N=752)	Percent of Total
Yes	283	88%	703	<b>93</b> %
No	35	11%	38	5%
Not documented	4	1%	11	2%
<u>CGM Used Reliably</u>	<u>A1c &gt; 8.5% (N=322)</u>	<u>Percent of</u> <u>Total</u>	<u>A1c &lt; 8.5%</u> (N=752)	Percent of Total
Yes	179	<b>56</b> %	615	<mark>82</mark> %
No	104	32%	48	6%
Not documented	39	12%	89	12%



# Interventions in CGM Utilization Project

Core team: Diabetes NP, QI Specialist, 2 Endocrinologists, Medical Student.

## **Changes implemented:**

- Patient questionnaire
- Standardized definition for documenting using CGM reliably
- Created and distributed a CGM tipsheet
- Added automatic billing to documenting CGM usage in SmartForm
- Collected feedback on CGM tipsheet



# Standardize "Reliably" for CGM Use

#### Open Diabetes LHS

DIABETES SUMMARY - FORM	Diat	betes Summary
Diabetes Summary		
Annual Laborator	Y Dia	abetes Summary
Immunization Rpt	Expa	nd Collapse All
Quarterly Labora	Äll	Conapse An
CGM Time in Ra	Date of	DM Visit
Depression Scrn	Review	r and a second se
Depression Flwsht	10/17/2	2024 💼
PedsQL Diabetes	> Ba	ckground Information
PedsQL Diab Scrn		
PedsQL Flwsht	<u> </u>	<u>:nnology</u>
	Does p	atient have access to continuous glucose monitor?
	Yes	No
	Does t	he patient reliably use the continuous glucose monitoring system?
	Yes	No
	Was th	e continuous glucose monitoring data reviewed during visit
	Yes	No
	Percen (TIR)	it Time in Range
	Glucos	e Monitor Table
		Type Start Date Stop Date
	1	Dexcom
	2	



# **CGM** Tipsheet



#### Tips for Wearing a Continuous Glucose Monitor (CGM)

If your continuous glucose monitor falls off sometimes, try these things to keep it in place. Find out how to handle other problems too.

#### **Basic Tips**

- Try placing your CGM on different parts of the body. Ask your provider for suggestions.
- Clean your skin of oils and lotions. Wash the site using a non-moisturizing soap like Dial®.
- After you insert the sensor, rub the dressing around the sensor to attach it securely.
- Use an overlay patch to hold your sensor in place.



Dexcom

#### How to Hold Your CGM in Place?

Try using a skin adhesive and a clear film dressing to help your CGM stay secure.

Libre

#### First, use a skin adhesive (like Skin Tac™ or Mastisol®)

#### Follow these steps:

- Wipe the Skin Tac or Mastisol in a donut shape at the insertion site. Let the adhesive product dry completely.
- 2. Insert the CGM sensor.
- 3. Wipe the tape, including edges, with the Mastisol or Skin Tac again. Let it dry completely.
- 4. When it is dry, place the overlay patch on top.
- At any time during the week, if the edges of the dressing come lose, wipe the edges with more Skin Tac or Mastisol.



#### How to Remove Your CGM?

If you have trouble removing the dressing before removing your CGM, try using TacAway<sup>®</sup> adhesive remover wipes or baby oil. Gradually rub at the outside edge of the tape and skin while slowly pulling the tape. Continue working inward until you reach the final edge of the adhesive, and the sensor comes off easily.

#### How to Avoid Irritated or Sensitive skin caused by the Sensor Adhesive?

Scan the QR code to read what to do.



#### Where to Buy Overlay Patches and Skin Adhesives?

You can buy overlay patches, skin adhesives, and adhesive remover wipes online or at a local retail store. Try Amazon, Walmart etc.

#### What to Do If Your Sensor Falls Off?

If your sensor falls off, contact your CGM company to get a replacement.

You can contact the company by going to their website and using the chat, reaching out to them on their app, or calling their support line.

For the Libre support line, call (855) 632-8658 or scan the QR code. For the Dexcom support line, call (844) 607-8398 or scan the QR code.





Dexcom

#### When to Contact Your CGM Company?

Call the company that makes your CGM if:

- Your sensor falls off too soon. The company will send you a replacement at no cost to you.
- You have a technical problem. (like a sensor error or you cannot connect your CGM to your phone.)
- When inserting your sensor, you have a lot of bleeding at the site and need a replacement sensor.

#### When to Contact Your Diabetes Care Team?



## Added Billing to CGM Documentation in Diabetes SmartForm

#### 💻 Open Diabetes LHS DIABETES SUMMARY Diabetes Summary FORM Diabetes Summary Diabetes Summary Annual Laborator... Immunization Rpt Expand Collapse All ÂII Quarterly Labora.. CGM Time in Ra... Date of DM Visit Review Depression Scrn Depression Flwsht 10/17/2024 Ē. PEDSQL DIABETES -**Background Information** > PedsQL Diab Scrn Technology PedsQL Flwsht Does patient have access to continuous glucose monitor? No Yes Does the patient reliably use the continuous glucose monitoring system? No Yes Was the continuous glucose monitoring data reviewed during visit Yes No

### Charge Capture Charges

Charge ID	Procedure Code	Description	Qty.	Modifiers	Charge Entry User	Diagnosis
103608238	99215	OFFICE/OUTPATIENT ESTABLISHED HIGH MDM 40-54 MIN	1	25	Hanley, Patrick, MD	Type 1 diabetes mellitus with hyperglycemia
103608614	95251	CONT GLUCOSE MONIT 72 HR PHYS INTERP	1		Hanley, Patrick, MD	Type 1 diabetes mellitus with hyperglycemia



# Run Chart for CGM Project



### % Using CGM Reliably & A1C > 8.5



Month Year

# Control Chart for Patients with A1c > 8.5%



NEMOURS CHILDREN'S HEALTH

Month Year

# Thank you for your time – questions or feedback?

Copyright 2005 by Randy Glasbergen. www.glasbergen.com

![](_page_48_Picture_2.jpeg)

"Your blood sugar is too high."

Patrick.Hanley@nemours.org

![](_page_48_Picture_5.jpeg)

# **Center Presentation**

![](_page_49_Picture_1.jpeg)

![](_page_50_Picture_0.jpeg)

DEPARTMENT OF PEDIATRICS

![](_page_50_Picture_2.jpeg)

### **Division of Pediatric Diabetes & Endocrinology**

# Texas Children's Diabetes Care

Daniel DeSalvo, MD Sarah Lyons, MD Selorm Dei-Tutu, MD, MPH

T1D Exchange QI Collaborative – January 2025 Pediatric Collaborative Call

![](_page_50_Picture_7.jpeg)

## Diabetes clinic information

## **Locations**

Houston: 6 clinics and 3 hospitals Austin: 1 clinic and hospital

## **Faculty and staff**

Pediatric endocrinologists: 35 Advanced practice providers: 9 CDCES FTE: 29 (includes 3 remote) RD FTE: 10 Social workers FTE: 6 Psychologists: FTE: 2

![](_page_51_Picture_5.jpeg)

DEPARTMENT OF PEDIATRICS

## FY2024 patient demographics

Type 1 population: 3396, new onset: 358/yr Insurance: 38% public Race/ethnicity: 40% non-Hispanic white, 31% Hispanic, 21% non-Hispanic Black, 8% other

**Type 2** population: 779, new onset: 124

![](_page_51_Picture_10.jpeg)

![](_page_52_Figure_0.jpeg)

![](_page_52_Picture_1.jpeg)

![](_page_52_Picture_2.jpeg)

# Diabetes Care Process Team Structure:

![](_page_53_Figure_1.jpeg)

![](_page_53_Picture_2.jpeg)

![](_page_53_Picture_3.jpeg)

![](_page_54_Figure_0.jpeg)

PEDIATRICS

Medicine

![](_page_54_Picture_2.jpeg)

![](_page_55_Figure_0.jpeg)

![](_page_55_Picture_1.jpeg)

Baylor DEPARTMENT OF PEDIATRICS

# 

Category	Classification	Metrics	IOM Domain
	Outcome	Emergency department visits/hospital admissions for potentially preventable events (established patients)	Effective, Safe
General	Process	Percentage of patients treated by providers and ancillary service within timeframes endorsed by national guidelines (includes new and established patients)	Effective, Timely
	Outcome	Percentage of children whose community providers have utilized educational tools within EPIC, patient-specific documents within EPIC (e.g., portable medical summary)	Care Coordination
Screening	Process	Adherence to screening procedures as defined by national guidelines for the following: cholesterol; blood pressure, thyroid disease; eye exam; micro albumin, celiac disease and depression	Effective, Efficient
	Outcome	Percentage of patients above HbA1c target (7.5) or poor control (>9) (stratify by age)	Effective, Safe
Treatment / Management	Structural/ Process	Development of a decision tree for strategies to address glycemic control (e.g., referrals for social work – psychology consult – diabetes educator vs. dietician – case management/care coordinator). Utilization of a risk-assessment score to determine the appropriate strategies described in the aforementioned measure	Effective, Efficient, Care Coordination
	Structural/ Process	Development of an educational pathway. Adherence to educational pathway (all patients will undergo initial training and are re-assessed on condition-specific topics)	Patient Centered

![](_page_56_Picture_2.jpeg)

![](_page_56_Picture_4.jpeg)

![](_page_57_Picture_0.jpeg)

### 2013

- Launch
- **Data analytics**
- **Balanced** scorecard
- Insulin guidelines
- Education handbook

### 2014

- Inpatient diabetes unit
- Order sets
- Nursing education pathway
- Family centered rounds

### 2015

- **Expansion to 5 teams**
- New onset risk score
- **Diabetes action plan**
- Hospital follow-up visit

### 2016

- Comorbidity screening
- Ancillary touchpoints ٠
- Diabetes psychologist ٠
- School orders
- National collaborative

### 2017

- **EMR** health registry
- Preclinic planning ٠
- High risk social worker
- Advanced education
- Community outreach ٠
- **TCHP** partnership •

![](_page_57_Picture_30.jpeg)

### 2018

- Readmission bundle •
- Clinic passport ٠
- **Psychosocial assessment** •
- School nurse conference

### 2019

- Access initiatives •
- Depression screening ٠
- Cholesterol management ٠

### 2020

- Telehealth •
- Food Insecurity ٠
- State Medicaid advocacy •

### 2021

- MyChart questionnaires
- Sick day visits •
- Advanced technology •
- Nurse coordinator .

### 2022

- Medical nutrition therapy
- Toddler diabetes program
- Hypoglycemia management ٠
- Prediabetes pathway
- Remote patient monitoring ٠ program

### 2023

- New to technology clinic ٠
- Transition to adult care •
- Type 1 prevention

### 2024

- AID system expansion
- Wrap around care for high-risk patients
- New onset type 2 pathway and med use

![](_page_57_Picture_63.jpeg)

![](_page_57_Picture_64.jpeg)

## DEPARTMENT OF

![](_page_57_Picture_69.jpeg)

# SIT Down T1D! - Screening & Intervention To Delay T1D

![](_page_58_Figure_1.jpeg)

![](_page_58_Picture_2.jpeg)

DEPARTMENT OF Baylor College of Medicine

# T1D Exchange QI Collaborative – T1D Screening Project

- <u>Collaboration with:</u>
  - Lurie Children's Hospital of Chicago
  - Children's National Hospital
  - University of Indiana
  - Rady Children's Hospital (UCSD)
  - University of Florida

![](_page_59_Picture_7.jpeg)

![](_page_59_Picture_8.jpeg)

# Fishbone Diagram – T1D screening and intervention

![](_page_60_Figure_1.jpeg)

![](_page_60_Picture_2.jpeg)

# Key Driver Diagram – T1D screening and intervention

### **INTERVENTIONS**

![](_page_61_Figure_2.jpeg)

monitoring with BG meter and/or isCGM, 3) +/- OGTT

Baylor DEPARTMENT OF College of Medicine PEDIATRICS

### T1D Screening Project: Implementation <u>Rolling Action Item List</u>

### AIM: Increase by at least 15% (from baseline) the proportion of people screened for T1D in 18 months. (June 2024- Dec 2025)

Key Driver	Intervention	PDSA	Point Person	Progress Note	Next Steps	Status
PCPs unaware of need for T1D screening	PCP education on T1D screening, staging, and prevention	<ol> <li>TCP live Webinar (Aug 2024) led by Lauren Culbreth and Dr. Aguirre</li> <li>Webinar was shared with external Pediatric offices (Oct 2024)</li> </ol>	Daniel DeSalvo	Webinar complete	Booster education	Adopted
No current model for T1D prevention clinic or mechanism for referral	Utilize new referral mechanism for PCPs	<ol> <li>PCP referral type update: "Screening and staging to delay type 1 diabetes" (Aug 2024)</li> <li>Algorithm for central scheduling at TCH update to schedule into SIT Down T1D clinic (Aug 2024)</li> <li>Education about new referral type at TCP Webinar (Aug 2024)</li> <li>Education about new referral type to TCH Pediatric Endocrinology faculty and fellows (Sep 2024)</li> <li>Based on feedback from TCP providers, change referral to "Pre-symptomatic screening for type 1 diabetes" with just 1 click</li> </ol>	Curtis Yee (practice administrator)		<ul> <li>Expand clinics once they are booked 3 months out</li> </ul>	Adopted
Patients/families unaware of need for T1D screening	Multimodal education to patients and families	<ol> <li>New onset binder (July 2024)</li> <li>Flier in exam rooms (Sep 2024)</li> <li>Future: MyChart letter to current T1D patients</li> </ol>	Melissa Marshall (Clinic Manager)	Binder and flier complete	Discuss plan for MyChart message	In- process
No current model for T1D prevention clinic or mechanism for referral	Schedule pre-diabetes referrals with normal BMI in SIT Down T1D clinic	<ol> <li>Meet with clinical lead for pre-diabetes – Dr. Horne (Oct 2024)</li> <li>Revise protocol so that pre-diabetes referral with BMI &lt;90th%, age &lt;10y, +autoimmune condition, goes to SIT Down clinic (Nov 2024)</li> </ol>	Dr. Horne and Curtis Yee	Referral algorithm • updated Nov 2024	Track progress	In- process
Patients/families feeling overwhelmed with diagnosis	Psychology involvement	<ol> <li>Meet with diabetes psychologists (Drs. Gallagher and Carreon) – Jan 2025</li> <li>Consider having separate telemedicine vs. shared medical/psychology visit</li> </ol>	Dr. Gallagher	Meeting Jan 2025	Pilot referrals	In- process
Families seeking interventions to aid in delay of Stage 3 T1D	Addressing nutrition	<ol> <li>Provider discusses avoidance of concentrated sweets</li> <li>Include Smartphrase in patient message (AVS) after visit concluded</li> <li>Consider referral to RD on case-by-case basis (Jennifer Cleveland, RD)</li> </ol>	Jennifer Cleveland, RD	Jennifer accepting • referrals	Pilot with Jennifer Cleveland	Adopted

# SIT Down T1D! - Screening & Intervention To Delay T1D

![](_page_63_Picture_1.jpeg)

• Telemedicine clinic with Lauren Culbreth, **PA-C** launched in June 2024

![](_page_63_Picture_3.jpeg)

- Epic Pop Health T1D Screening Registry, Smartform, documentation, dashboard, and reports
- PCPs can refer siblings for "Screening and staging to delay type 1 diabetes"
- TCP webinar with PCPs August 2024

![](_page_63_Picture_7.jpeg)

Baylor College of Medicine

![](_page_63_Picture_9.jpeg)

# SmartForm for T1D Screening & Staging

Diabetes Intake							
Diabetes staging (puts	Pre-screening (a	Pre-screening (autoantibodies not yet obtained)			Screening (all autoantibodies negative)		
registry)	Screening (only	1 autoantibody positive	)	Stage 1 T1	)		
	Stage 2 T1D			Stage 3 T1	)		
Family member wtih	Sibling	Aunt	Aunt 2nd Cou		No known	wn family members v	
ΠD	Mom	Uncle	Gran	dmother	Other		
	Dad	1st Cousin	Gran	dfather			
Stage 1 T1D status	known NA	unknown othe	r				
Stage 1 T1D date							
Stage 2 T1D status	known NA	unknown othe	r				
Stage 2 T1D date							
Method of detecting	Fasting BG	Random BG		HbA1c		OGTT	
dysglycemia	CGM	Other					
Stage 3 T1D status	known NA	unknown othe	r				
Stage 3 T1D date							
Positive antibodies	GAD65 Glutami	acid decarboxylase 65		IA-2A Ins	ulinoma-assoc	iated antigen 2	
	IAA Insulin auto	antibody		ICA Islet	cell autoantibo	dy	
	ZnT8 Zinc transporter-8 autoantibody			No positi	No positive antibodies		
	Antibodies have	not been checked		Other			
Antibody testing	Quest Diagnosti	cs		TCH Lab			
source	LabCorp			Other commercial lab			
	TrialNet			Autoimmunity Screening for Kids (ASK)			
	Enable Biosciences (online ordering)			Antoodi	es have not be	en checked	
	Other						
Is the patient	Ves with CGM	Yes with blood	alucose r	meter No		Other	

Has patient received teplizumab (TZIELD)? (if yes, puts patient on TZIELD registry)	yes no				
Has the patient received any other diabetes prevention medications?	yes no				
What diabetes prevention medications has the patient received?	test				
Teplizumab (TZIELD	) Details				
Date teplizumab (TZield) was received (start date)					
Did patient receive all 14 doses of TZield?	yes no				
TZIELD infusion	All doses received in TCH inf	usion center			
location	All doses were received at outpatient infusion center other than TCH				
	All doses were given in home setting by infusion center other than TCH				
	Business days at infusion cer	nter / weekends home healtho	are infusion		
	Hybrid model (explain)				
What significant side	cytokine release syndrome	leukopenia / lymphopenia	serious infection		
effects did the patient experience?	hypersensitivity	rash	elevated LFTs (AST >3x upper limit		
	none	other			

![](_page_64_Picture_3.jpeg)

![](_page_64_Picture_5.jpeg)

# T1D Screening & Staging Registry - Dashboard

Epic       MW ENDOCRINE CLNC - Epic Production - DANIEL DESALVO         #E Patient Lists       Chart       In Basket       Patient Station       ED Track Board         Image: Patient Lists       # Chart       In Basket       Patient Station       ED Track Board         Image: Patient Lists       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Lists       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Lists       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Lists       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Lists       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Station       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Station       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station         Image: Patient Station       # ED Track Board       Image: Patient Station       Image: Patient Station       Image: Patient Station	Search (Ctrl+Space)     Personalize      Powntime CSN Outbreak Tools      The Ambra Image Sharing TCH OR Discharge Tracking	▲ +1       □       +1       □       ↓       ●
TCH Diabetes Prevention Dashboard -		(III - Y O (I
T1D Prevention Registry Summary         © Report completed: Fri 1/24 10:56 AM         Staging       Number of Patients         Pre-screening (autoantibodies not yet obtained)       6         Screening (all autoantibodies negative)       9         Screening (only 1 autoantibody positive)       14         Stage 1 T1D       12         Stage 3 T1D       2         Count unique values       50	TZIELD Registry Staging Summary w/Family Member         © Report completed: Fri 1/24 10:58 AM         Staging       Number of Patients         Pre-screening (autoantibodies not yet obtained)       0         Screening (all autoantibodies negative)       0         Screening (only 1 autoantibody positive)       0         Stage 1 T1D       0         v Stage 2 T1D       4         1st Cousin       1         Dad       1	TZIELD Side Effects © Report completed: Fri 1/24 10:58 AM
Registry Reports         Last Refresh: 10:56:09 AM         Registry Reports         T1D Prevention All Patients Report         TZIELD Registry Report         Coordination Reports         Antibody Lab Report (prescreening/screening)         Antibody Lab Report (stage1/2)	No known family members with T1D     2       Sibling     1       Count unique values     4       TZIELD Registry Antibody Summary     4       © Report completed: Fri 1/24 10:58 AM     Number of Patients       GAD65 Glutamic acid decarboxylase 65     4	
	IA-CA insulinoma-associated antigen 2     2       IAA Insulin autoantibody     1       ICA Islet cell autoantibody     2       ZnT8 Zinc transporter-8 autoantibody     3       [No Value]     0	I leukopenia / I none I to other I rash

![](_page_65_Picture_2.jpeg)

![](_page_65_Picture_4.jpeg)

**SMART Aim**: Increase, by at least 15% (from baseline), the proportion of people screened for T1D in 18 months (from June 2024 – December 2025)

![](_page_66_Figure_1.jpeg)

Baylor College of Medicine

![](_page_67_Picture_0.jpeg)

DEPARTMENT OF PEDIATRICS

![](_page_67_Picture_2.jpeg)

![](_page_67_Picture_3.jpeg)

![](_page_67_Picture_4.jpeg)

# The state of T1D at Texas Children's Hospital in 2021

- Over 5 years, A1c trend barely budging
- Widening gap between privately and publicly insured status

![](_page_68_Figure_3.jpeg)

![](_page_68_Picture_4.jpeg)

![](_page_68_Picture_5.jpeg)

# We needed a paradigm shift in care...

## HELEONA M. AND HARRY B. CHARITABLE TRUST

Diabetes Clinic Initiative 2021 Request for Proposal (RFP) Overview

#### Purpose

The Leona M. and Harry B. Helmsley Charitable Trust's (Helmsley) Type 1 Diabetes (T1D) Program is launching a limited Request for Proposals (RFP) for nonprofit diabetes clinics throughout the United States. The RFP's goals are: 1) to enable innovative projects for telemedicine, diabetes technology, research, and alternative care models; 2) to encourage junior faculty to propose novel ideas; 3) to address some of the key clinical barriers and inefficiencies to providing quality care. The overarching purpose of the Diabetes Clinic Initiative RFP is to support clinics to empower people with T1D (including their caregivers) in taking care of their diabetes, improve their health outcomes, and quality of life.

#### **RFP Goals**

Helmsley's Type 1 Diabetes program's mission is to improve the lives of people living with T1D. We strive to achieve our mission by increasing access to quality care and diabetes technologies, as well as increasing adoption of diabetes technologies. All people living with T1D should have access to the best care and tools to manage their disease regardless of where they live.

The Diabetes Clinic Initiative RFP seeks innovative projects in the following broad strategic areas:

- Telehealth (e.g. remote patient monitoring approaches within and/or beyond clinic borders, addressing workflow issues, expanding the reach of services provided by scalable workforces such as CDCES(s), social workers, data generation for building evidence to increase access to telehealth, etc.)
- Adoption of Diabetes Technologies (e.g. innovative approaches for increasing adoption and persistent use of tech within and/or beyond clinic borders)
- Decision Support integration into clinical care (for providers and PWDs)
- Equip, empower and education of people with T1D (e.g., for diabetes technologies, data downloads, tech, and insurance navigation)
- Collaborative projects between endocrine and primary care
- Multi-stakeholder projects (e.g., involving payer, health systems, PCP's, pharmacists, psychologists, behavioral health therapists, and other relevant practices)
- Integrated care approaches (e.g., integration of behavioral health with diabetes care)

![](_page_69_Picture_15.jpeg)

## And at that time, the Helmsley Charitable Trust announced a Diabetes Clinic Innovation grant

Baylor College of Medicine PEDIATRICS

# ROCKET T1D RPM Program

![](_page_70_Picture_1.jpeg)

ROCKET<u>Remote Outreach & Care</u>for <u>K</u>ids' <u>Empowerment</u>and <u>T</u>echnology use in <u>T1D</u>

**Overarching Aim**: To empower youth and their families to leverage emerging technology, improve diabetes selfmanagement habits, and achieve their self-care goals to thrive with T1D

![](_page_70_Picture_4.jpeg)

![](_page_70_Picture_5.jpeg)

![](_page_70_Picture_6.jpeg)

# 3 Major Components of Project

![](_page_71_Picture_1.jpeg)

1) Remote patient monitoring (RPM):

via EMR diabetes registry and Glooko Population Tracker

![](_page_71_Picture_4.jpeg)

DEPARTMENT OF PEDIATRICS

![](_page_71_Picture_6.jpeg)


**Launch**: Active participation phase with clinical outreach focused on diabetes management habits

**Orbit**: RPM phase with periodic data review and therapy adjustment if needed

### **Target Population**:

- 1. All new onset T1D patients
- 2. Established patients with
  - Moderate to high RI-DKA score
  - Starting new technology
  - Recent DKA





## **ROCKET** Intervention: Remote Patient Monitoring

#### **Care team**

### **Remote platform**

3 CDCES for Established Launch and Orbit

2 CDCES for new onset Launch

#### Fellow

Social Worker  $\rightarrow$  Community Health Worker

Program coordinator

PEDIATRICS

PIs and Co-Is

Mission Control Meetings

Cloud-connected device data Communication via -telehealth visits -MyChart -Phone: ROCKET T1D line

#### **Education & goals**

ROCKET T1D 'Flight manual'

-Diabetes self managements habits

-Sick day management

-Troubleshooting devices

-Other family goals related to T1D









**ROCKET** Process Map







## EMR Tools: TCH Diabetes Registry





DEPARTMENT OF PEDIATRICS





## RPM using Glooko Population Tracker

	glooko Name	<ul> <li>C Enter a patient name</li> </ul>		TCH - Pediatric Endocrinology - DD - ProConnect Code: tchpeds - DD -	
	Assign Devices	View Patients	Switch to legacy patient list	Create Patient Account	
	Filter Patients  1-15 of 5031				
	Q Search Filters	et Sume	Eleas	Tage	
	Provider Daniel DeSalvo No Provider	st sync	Last run on 2023-06-15	1982	
		day		+	
	Tag Extra care/at-risk (main campus) Rocket t1d - orbit phase Rocket t1d - launch phase	•day		+	

- ✓ Syncs data in real-time
- ✓ Access remote data on-demand as interactive reports
- ✓ EMR integration





### Launch Phase: Anchored by the 6 Habits

向



Original Investigation | Diabetes and Endocrinology Feasibility of Electronic Health Record Assessment of 6 Pediatric Type 1 Diabetes Self-management Habits and Their Association With Glycemic Outcomes

Joyce M. Lee, MD, MPH; Andrea Rusnak, MS; Ashley Garrity, MPH; Emily Hirschfeld, BA; Inas H. Thomas, MD; Michelle Wichorek, PhD; Jung Eun Lee, MS; Nicole A. Rioles, MA; Osagie Ebekozien, MD, MPH, CPHQ; Sarah D. Corathers, MD

In collaboration with Joyce Lee, MD MPH; Ashley Garrity, MPH; and Justine Ross











### ROCKET T1D Flowsheet & Dashboard

8	🐱 - 🛛 📇 Chart   👌 Content Management 🔎 My Reports 👕 Rule	e Editor 🥒 Column Editor 🛄 Exte	nsion 🎁 Registry Editor 🅜 Grouper Edito	r   🕌 Record Viewer 🕌 Compar	re Record 📱 Session I	Information Report	💛 uLearn 🄌 🛃 Help Desk 🌏 🔒 Print 🗸 🔂 Log Ou
	🛗 😝 💭 🛱 Data Courier	Inpatient Admin	🛛 Reports 🛛 🗙				POC KELLY D. TIMMONS
•	Endocrine ROCKET T1D: Patients Du	e For Follow Up Next	7 Days [9829026] as of Fri	7/29/2022 9:31 AM			() v
	🚰 Chart 🗣 Encounter 👻 🖾 Communication 👻 🖉	Results Review 🕂 Questionnaire	Series - 🛞 Research Studies				🚞 Detail List - Original
My R	eports Detail List Explore						
Flowsheets		с к.					Re-run Report C Refresh Selected Select All
🖶 Elle 🗄 Add Bows 🕂 LDA Avatar 🔹 📊 Add Col 📲 ninsert Col 📑 Last Filed 🔹 Reg Doc 🔄	Graph 🝷 🛱 Gg to Date 🦂 Responsible More	Follow Up Date	Follow Up Need RT1D Assigned Te	eam Launch FYI Orbit FYI	RT1D Phase D	iabetes Type Date of Dx	Pump? CGM'∕ 0⊮A Risk Score Las A1c Date
Complex Vital Signs Intake/Output LDA Assessment Respiratory Flowsheet ROCKET 1	1D Intake + ROCKET T1D Int	08/05/2022	Other Mission A (Med Center)	7/15/2022	Orbit (Phase 2)	Type 1 03/09/2020	2 09/18/2020
C Expanded View Ad	1m 5m 10m 15m 30m 1h 2h 4h 88 Note Only from 6/5. 6/5/2023	08/01/2022	Check in Week 3 Mission A (Med Center)	i 7/18/2022	Graduated from ROCKET T1D Program	Type 1 11/03/2014	0
P Search (Alt+Comma)	1200						
ROCKET TID Details							
<b>⊊</b> ≣Phase	01	100					
6 Self-Management Habits	Launch: established T1D (Phase 1)						
Habit #1: Blood glucose checking frequency on download	Launch: new onset T1D (Phase 1)						
Habit #2: Average # of bolus insulin doses per day on download (for pump) and patient report i	Launch: withdrawal						
Habit #3: Type of intensive therapy	Launch: graduation/nol (are gressing to orbit						
Habit #4: Timing of insulin with meals	Orbit (Phase 2)						
Habit #5: Times blood glucose or insulin data were downloaded and reviewed for blood glucos	Orbit: withdrawal						,
Habit #6: Times insulin was adjusted by family or by diabetes team since the last diabetes clini	Graduated from ROCKET T1D Program	Dcial 📙 Care Team / Visit	Details 📱 Risk Profile 📳 DKA Risk Trend	Registry Details			
CDCES ROCKET T1D Follow Up	1 Mart Day	_	Allergies ?		+	Outpatient Medication	Meds Overview
CDCES Follow Up Date	4 Next How		C Enable clinical decision suppo	art by reconciling outride inform	ation 4	Enable clinical decision supp	ort by reconciling outside information a
CDCES Follow Up Need	×	]	Azithromycin     High - Hives     Fish-derived Products     High - Anaphylaxis     Amoxicillin	Y Cefzil [cefprozil] High - No reactions s     Penicillins ℓ High - Hives, Itching,     Lanolin ℓ	specified ac Gi Rash an	etaminophen PO CHEW TAE ve 1 Tablet by mouth every 6 h in or fever, temp >101F. mphetamine/dextroampheta	Last Edited 160 mg 9 months ago ours as needed for mine (ADDERALL 1 year ago
	Updated 3 years ago - Tch Rn Int DI Test RN CF Summary & Needs	e	Medium - Itching	Medium - Itching, Sw	velling Gi	ve 10 mg by mouth.	cg/spray 1 year ago 2 result





### 3 Major Components of QI, Clinic Innovation Project







### History of Predictive Analytics at TCH

2013	RI-PGC developed and in Epic
2015	RI-DKA developed and in Epic
2019	Extra Care cohort developed with dedicated SW
2021	High Risk care team (SW and RN) start using RI-DKA with patients
2023	Pt outreach encounter developed; HELLO and REACH registry built

Baylor

College of



### **RI-DKA Score**

> Clin Diabetes. 2022 Spring;40(2):204-210. doi: 10.2337/cd21-0070. Epub 2022 Apr 15.



### An Automated Risk Index for Diabetic Ketoacidosis in Pediatric Patients With Type 1 Diabetes: The RI-DKA

David D Schwartz<sup>1</sup>, Rosa Banuelos<sup>2</sup>, Serife Uysal<sup>3</sup>, Mili Vakharia<sup>3</sup>, Kristen R Hendrix<sup>34</sup>, Kelly Fegan-Bohm<sup>3</sup>, Sarah K Lyons<sup>3</sup>, Rona Sonabend<sup>3</sup>, Sheila K Gunn<sup>3</sup>, Selorm Dei-Tutu<sup>3</sup>

Affiliations + expand PMID: 35669298 PMCID: PMC9160557 DOI: 10.2337/cd21-0070 Free PMC article





Score	Category
-3.5 – 2	Low risk
2.5 – 6.5	Medium risk
7 – 10	High risk
10.5 – 14	Very high risk









### HELLO vs REACH

HELLO (help for youth with elevated glucose levels to improve outcomes)

• Youth with T1D at moderate risk of DKA (RI-DKA score between 2.5 - 7)

REACH (<u>re</u>sources <u>and</u> <u>care</u> to improve <u>h</u>ealth outcomes)

• Youth with T1D at high risk of DKA (RI-DKA Score >7 or h/o multiple DKA episodes in past year)





### REACH Intervention Examples



noom #							
Patient Name:		Provider:					
Appointment Time: _	ime: Patient Label:						
Diabetes Clinic Checklist							
	To be Done today:	Completed today:	Notes:				
Lipid Panel:							
TSH:							
Micro-albumin:							
Retinal Exam:			Last Retinal Exam:				
Flu Vaccine:							
Psychology:			РНО-9 DKA				
PHQ- 9:			Score: Risk Score:				
Social Worker: Dinsulin affordal Diabetes burno Depression/sui Basic Need Inse Lack or no insu	D bility out/distress/non-ac icidal ideation ecurity (Transporta rance	□ Iherence Ition/food scarcit	□ Please See Provider First y risk)				
<ul> <li>Transition to adult care/college</li> <li>Disability</li> <li>Support groups</li> <li>Medical power of attorney</li> <li>Immigration</li> <li>504 Plan</li> <li>Other</li> </ul>							



DEPARTMENT OF PEDIATRICS

Baylor College of

### Epic Tools to Enable Proactive Care







### **REACH Scorecard**

				Relative %			
		4 /7 /2025		change over	Prior Month		
REACH Metrics of Interest		1/7/2025	AVg 2024	2024 Avg	12/5/2024	Improvement	
HbA1c	mean	11.00	11.27	2%	11.1	lower good	increase bad
%>12		0.34	0.42	12%	0.37	lower good	increase bad
%<9		0.19	0.19		0.21	increase good	lower bad
%<7.5		0.03	0.03		0.03	increase good	lower bad
ED Visits after enrollment	0.33	0.29	-22%	0.35	lower good	increase bad	
DKA past 12 mo.		0.38	0.44	14%	0.38	lower good	increase bad
RI-DKA Score	mean	7.90	8.80	9%	8.00	lower good	increase bad
Pump use		0.37	0.30	-19%	0.36	increase uptake good	decrease bad
CGM use	0.70	0.64	-6%	0.68	increase uptake good	decrease bad	
PHQ9 administered	0.22	0.17	-5%	0.18	increase uptake good	decrease bad	







Baylor College of









## Community Health Worker Program



Meghan Craven, MD, MPH Adrina Jones, CHW

### Extension of the Extra Care team with focus on 5 goals:

- Improve appointment management and communication with the care team
- Increase access to healthy food
- Navigate barriers to access in diabetes technology
- Apply for **public benefits** and patient assistance programs
- Support **transition** to adult care provider





### Examples of Community Health Worker support

#### **Connect to community resources**

- Utility assistance
- Cellphone service
- Rent assistance
- Career center
- Diaper depot
- Food pantry

#### Assist with applications

- SNAP benefits
- County healthcare services

#### Assist with appointments

- Pump training
- Clinic visits

DEPARTMENT OF

PEDIATRICS

Baylor College of



# Thank You



rebecca.aguirre@bcm.edu lauren.culbreth@bcm.edu desalvo@bcm.edu



DEPARTMENT OF PEDIATRICS

